The presence of low serum albumin and crazy paving ground glass opacities on high-resolution computed tomography at the time of non-HIV Pneumocystis jirovecii pneumonia diagnosis were predictive of poor prognosis.
A novel antibiotic, lefamulin, may not be inferior to moxifloxacin in efficacy and safety for the treatment of community-acquired bacterial pneumonia.
Expert opinions on judgment-based criteria for the assessment of antimicrobial treatment efficacy in HABP and VABP are heterogenous.
Researchers conducted a post hoc analysis on antipneumococcal antibody responses in patients with SLE previously immunized with the 23-valent pneumococcal polysaccharide vaccine.
A new algorithm can search administrative data for individuals with HAP and VAP, who are at significant risk for carbapenem-resistant infection.
A double-blind trial found omadacycline to be noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia.
Patients who either are currently or have recently taken benzodiazepines may have an increased risk for pneumonia.
Patients diagnosed with community-acquired pneumonia with higher levels of fibroblast growth factor-21 may have higher mortality rates and longer hospitalizations.
Diagnosing coinfection in pneumonia can be challenging because of timing of the sample collection and false-negative results when the viruses replicate in the lower respiratory tract.
The diagnostic criteria for community acquired pneumonia within randomized controlled trials are highly heterogeneous.
